Company Overview

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and advancement of antibody-based therapeutics for oncology indications. The company operates within the biopharmaceutical and oncology drug development industries, with a core emphasis on leveraging computational biology and proprietary antibody discovery platforms to identify novel therapeutic candidates.

The company’s primary value driver is its pipeline of monoclonal antibody and antibody-based combination therapies designed to modulate immune responses and tumor biology. Compass Therapeutics primarily serves the oncology clinical and research market, targeting patients with solid tumors and hematologic malignancies through investigational therapies evaluated in clinical trials. Founded in 2014, the company evolved from an early-stage antibody discovery enterprise into a publicly traded clinical-stage biotech following its initial public offering in 2020, using public capital to advance its pipeline into human studies.

Business Operations

Compass Therapeutics generates no commercial product revenue and operates primarily through research and development activities, with expenditures focused on preclinical research, clinical trials, manufacturing of clinical trial materials, and regulatory activities. Its operations are centered on the discovery and development of therapeutic antibodies, including bispecific and multispecific antibody constructs, enabled by internal computational modeling and biologics engineering capabilities.

The company conducts its clinical and development activities primarily through outsourced partnerships with contract research organizations, contract manufacturing organizations, and academic collaborators. Compass Therapeutics does not currently report distinct operating segments, as its activities are managed as a single reportable segment focused on oncology drug development. Data on material joint ventures or revenue-generating subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Compass Therapeutics is focused on advancing its lead oncology programs through clinical development while expanding its pipeline through internal discovery efforts and selective external collaborations. Its growth strategy emphasizes capital-efficient development, strategic partnerships, and leveraging platform technologies to generate multiple therapeutic candidates from shared scientific infrastructure.

Key investments are concentrated in clinical-stage assets, including investigational antibody therapies targeting immune pathways relevant to cancer progression and treatment resistance. The company has also pursued licensing and collaboration arrangements to support development and potential commercialization, although it has not announced transformative acquisitions of late-stage or commercial assets. Its involvement in emerging sectors includes immuno-oncology, antibody engineering, and computational drug discovery, with ongoing evaluation of next-generation biologic modalities.

Geographic Footprint

Compass Therapeutics is headquartered in the United States, with its principal executive offices located in Massachusetts. Its operational footprint is primarily domestic, encompassing research, development, and corporate management activities conducted within the U.S.

Internationally, the company’s presence is indirect and largely driven by clinical trial activity and third-party partnerships. Clinical studies may be conducted across multiple regions, including North America and Europe, depending on trial design and regulatory requirements. The company does not currently report significant owned international facilities or large-scale overseas operations based on publicly available disclosures.

Leadership & Governance

Compass Therapeutics is led by an executive team with experience in biotechnology, drug development, and corporate leadership. The company emphasizes a strategic vision centered on disciplined clinical execution, scientific innovation, and long-term value creation through oncology-focused therapeutics.

Key members of leadership and governance include:

• Thomas Schuetz, MD, PhD – President and Chief Executive Officer
• Adam Scott, PhD – Chief Scientific Officer
• Jonathan Young – Chief Financial Officer
• Martin Foster, PhD – Chief Operating Officer

The company is governed by a board of directors with backgrounds in biotechnology, finance, and healthcare, providing oversight of strategy, risk management, and corporate governance consistent with public company standards.